VALFIX Medical receives European Commission's Seal of Excellence

TEL AVIV, Israel - June 9, 2020 - PRLog -- The European Commission recently awarded VALFIX Medical with the Seal of Excellence, a high-quality certificate for first-class innovative ideas worthy of investment. VALFIX Medical is developing the first complete trans-catheter solution that combines repair and replacement treatments for Heart-Failure patients suffering from severe Mitral Regurgitation (MR); offering a viable alternative to open-heart surgery.

VALFIX submitted a proposal with the European Commission's Horizon 2020 SME funding program. After an extensive review by an international panel of independent experts, VALFIX received the Seal of Excellence meaning VALFIX surpassed the quality threshold and the European Commission recommends VALFIX proposal for funding.

"For us at VALFIX Medical it is an honor to have our efforts recognized by the European Commission. This recognition is incredibly fulfilling as it comes from an international panel of independent experts in a highly competitive evaluation process," commented VALFIX Medical's CEO and Founder, Eli Bar. "We are proud that our project scored so highly against nearly 2000 applicants and this award reinforces our commitment to integrating innovation and quality as a value and approach in all of our work."

Receiving the Seal of Excellence means the European Commission recognizes VALFIX Medical as a highly innovative company with clear potential to compete internationally in a high-growth market.

About the European Commission's Seal of Excellence:

The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020, the EU's research and innovation funding program, to help these proposals find alternative funding. Projects which passed the stringent selection and award criteria but could not receive funding due to Horizon 2020 budget limitations, receive the Seal of Excellence. It recognizes the value of the proposal and helps other funding bodies take advantage of the Horizon 2020 evaluation process.

For more information visit http://www.ec.europa.eu/research/soe

About VALFIX Medical:

VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral valve; offering a viable alternative to open heart surgery.

To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com